
BDTX Stock Forecast & Price Target
BDTX Analyst Ratings
Bulls say
Black Diamond Therapeutics Inc is well-positioned for significant growth due to several anticipated catalysts that could potentially drive its stock price up by over 100%. The company is expected to generate substantial forecasted sales of approximately $500-750 million, particularly if it achieves a favorable overall response rate (ORR) in late 2025, which aligns with prevailing merger and acquisition valuations in the oncology space. Additionally, the strong efficacy of its lead candidate, silevertinib, against a variety of oncogenic mutations could enhance investor confidence and underscore the viability of its therapeutic approach in treating patients with actionable mutations, strategically positioning the company for long-term success.
Bears say
Black Diamond Therapeutics Inc faces a negative outlook primarily due to low investor confidence in its lead drug, silevertinib, particularly in the treatment of EGFRm non-small cell lung cancer (NSCLC), as reflected in its market cap of approximately $230 million. Concerns are amplified by the potential underdosing of silevertinib and the risk associated with phase 3 trial results, which may not meet efficacy expectations if the tested population proves less sensitive to treatment. Additionally, investor disappointment following recent clinical updates further complicates the company’s prospects and diminishes confidence in its competitive position within the oncology market.
This aggregate rating is based on analysts' research of Black Diamond Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
BDTX Analyst Forecast & Price Prediction
Start investing in BDTX
Order type
Buy in
Order amount
Est. shares
0 shares